MarketPulse

OV329

2 articles
The Motley FoolThe Motley Fool··Lee Samaha

Ovid Therapeutics Surges 18% on Positive Phase 1 Data for OV329 Epilepsy Drug

Ovid Therapeutics surges 18% after Phase 1 data shows OV329 epilepsy drug eliminated safety concerns. Company secures $60M to fund Phase 2 trials.
OVIDbiotechprivate placement
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ovid Therapeutics Raises $60M in PIPE Funding to Accelerate Rare Disease Pipeline

Ovid Therapeutics secures $60M in PIPE funding led by Point72 to advance OV329 development in rare neurological diseases including tuberous sclerosis complex and infantile spasms.
OVIDPIPE financingOV329